Prenatal Testing for Alström Syndrome: Options Explained

If you and your partner are both known carriers of an ALMS1 mutation, every pregnancy carries a 25% chance the baby will have Alström Syndrome. Prenatal and pre-pregnancy testing options exist for couples who want to know — or who want to plan around — that risk. This article explains each option, when it's done, what it can and cannot tell you, and the practical and ethical considerations involved.

This guide is most relevant for:

• Couples who have already had a child with Alström and are considering another pregnancy
• Couples where carrier screening (often during a current pregnancy) has identified that both partners carry an ALMS1 mutation
• Couples with a family history of Alström who are planning their first pregnancy
• Anyone weighing reproductive choices who wants accurate information about the testing landscape

Decisions in this space are deeply personal. There is no universally right answer — only the right answer for your family. A genetic counselor with experience in recessive conditions is invaluable.¹

Before invasive testing makes sense, both partners need to know their carrier status. If you've already had an affected child, both your ALMS1 variants are typically already known. If you're at the planning stage, your genetic counselor will arrange targeted ALMS1 sequencing for both partners.²

A 25% recurrence risk applies only when both partners are carriers. If one partner is a carrier and the other isn't, the child cannot have Alström Syndrome (though there's a 50% chance of being a carrier themselves).

PGD allows couples to test embryos for ALMS1 mutations before transferring them to the uterus.

How it works

1. The couple undergoes IVF to create embryos. 2. At day 5–6 of embryo development (blastocyst stage), a few cells are biopsied from the trophectoderm (the part that will become the placenta). 3. The cells are tested for the family's specific ALMS1 mutations. 4. Only embryos identified as unaffected (and ideally non-carrier) are transferred.

Pros

• Avoids the decision of whether to continue an affected pregnancy
• Provides high accuracy when the family's specific variants are known
• Can be combined with screening for chromosomal abnormalities (PGT-A)

Cons

• IVF is physically and emotionally demanding
• Cost is substantial and varies dramatically by country and insurance — often US$15,000–30,000 per cycle in the US, often unfunded
• Success rates vary by maternal age and other factors
• Some couples have ethical concerns about discarding affected embryos

Who might consider it

Couples who want to avoid the possibility of terminating an affected pregnancy, or those already pursuing IVF for other reasons.

CVS is performed between 10 and 13 weeks of pregnancy. A small sample of placental tissue is taken either through the cervix or via a needle through the abdomen, then tested for the specific ALMS1 variants.³

Pros

• Earlier than amniocentesis, allowing earlier decisions
• High diagnostic accuracy

Cons

• Approximately 0.5–1% miscarriage risk above the baseline pregnancy risk
• Done while pregnancy is established
• Can have rare placental mosaicism that complicates interpretation

Amniocentesis is performed from 15 weeks onward. A small amount of amniotic fluid is taken with a needle through the abdomen, then tested for ALMS1 variants.

Pros

• Slightly lower miscarriage risk (~0.1–0.3% above baseline)
• Highly accurate when the family's mutations are known

Cons

• Performed later in pregnancy, which compresses decision timelines
• Procedure-related discomfort

NIPT analyzes fetal DNA fragments circulating in the mother's blood. It's widely used to screen for chromosomal aneuploidies (Down Syndrome and others) but is much less developed for recessive single-gene disorders. As of 2026, NIPT is not a reliable definitive test for ALMS1 mutations and shouldn't be used as a substitute for CVS or amniocentesis.⁴

NIPT for monogenic conditions is an active area of research, and the picture may change in the coming years.

Talk to a genetic counselor before deciding

A genetic counselor walks through the options without pushing toward any one of them. They'll help you understand the testing accuracy, the procedure risks, the costs, and the timing.

Get your specific mutations on file

Each family's ALMS1 mutations are different. The lab doing prenatal testing needs to know exactly which variants to look for. If both your variants are documented from your affected child's diagnosis, you're in a strong position.

Consider your timeline

CVS at 10–13 weeks gives you the most time to consider results. Amniocentesis at 15+ weeks compresses the timeline. PGD with IVF requires planning months in advance of pregnancy.

Check insurance coverage

Coverage varies by country, plan, and case. In the US, some insurers cover CVS and amniocentesis when there's a documented family history but may not cover PGD. In the UK, NHS coverage for PGD requires meeting specific clinical commissioning criteria. Cost can be a substantial factor in the decision.

Some carrier couples decide that prenatal testing isn't the right fit. Other paths include:

• Conception with egg or sperm donation — using a non-carrier donor eliminates the recurrence risk
• Adoption — many families with one affected child grow their family this way
• Choosing not to have additional biological children — a complete and valid choice

The point isn't which option is best in general — it's which is best for your family. A counselor can support whichever direction you take.

• Genetic Counseling for Alström Syndrome Families
• Family Planning Options When You're an Alström Carrier
• Are Both Parents Carriers? Understanding ALMS1 Carrier Status
• Risk to Siblings of a Child With Alström Syndrome
• How Is Alström Syndrome Inherited?

April 30, 2026.